Myelofibrosis: meeting the needs of the ruxolinitib-resistant/intolerant?

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In a phase 2 study, the Janus kinase-2 (JAK2)-selective inhibitor fedratinib delivered meaningful clinical benefit to ruxolitinib (Jakafi)-resistant/intolerant patients with myelofibrosis.
  • Further study is required to elucidate toxicities.

Why this matters

  • 50% of patients ...